We are international
Donate
TEXT SIZE   
Press Release Archive

The IMF is making news all year round.

Press Release Archive
12.17.08  Mozobil™ Approval Could benefit Myeloma Patients Undergoing Autologous Stem Cell Transplants
The FDA Has Granted Marketing Authority for Mozobil with Granulocyte-Colony Stimulating Factor in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma

12.02.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS PATIENT EXPERIENCE—LONGER SURVIVAL AND IMPROVED QUALITY OF LIFE—SUPPORTS ENCOURAGING DATA BEING PRESENTED AT THE ANNUAL HEMATOLOGY MEETING
Treatment Progress Takes on New Urgency as Incidence of Myeloma Continues to Rise

11.18.08  THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES NEW THREE-WAY RESEARCH AGREEMENT WITH NOBEL PRIZE WINNER LUC MONTAGNIER AND HOWARD URNOVITZ OF CHRONIX BIOMEDICAL
Will Study Circulating DNA as a Marker for and Potential Cause of Disease Recurrence

11.06.08  THE INTERNATIONAL MYELOMA FOUNDATION CALLS FOR ALL PATIENTS TO HAVE ACCESS TO THE NOVEL THERAPIES FOR MYELOMA
"We support efforts that put patients first… and work for better outcomes until there is a cure," Susie Novis, IMF President

10.08.08  THE INTERNATIONAL MYELOMA FOUNDATION CONGRATULATES FRIEND AND COLLABORATOR DR. LUC MONTAGNIER FOR BEING AWARDED THE NOBEL PRIZE
Renowned French Scientist Instrumental in Studying the Role of Viruses in Multiple Myeloma

10.02.08  THE INTERNATIONAL MYELOMA FOUNDATION RECEIVES HEALTH IMPACT AWARD FOR EXCEPTIONAL SERVICE TO MYELOMA PATIENTS AND COMMUNITY
The Wellsphere Health Impact Award honors individuals and organizations making the greatest impact in the lives of patients.

09.29.08  THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS EXPANSION OF VELCADE® FOR PREVIOUSLY UNTREATED PATIENTS IN EUROPE AND CANADA
With these new approvals, patients with multiple myeloma may now receive VELCADE earlier following an initial disease diagnosis.

09.25.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS LIFE-CHANGING BENEFITS OF REVLIMID® RECOGNIZED BY THE PRESTIGIOUS PRIX GALIEN USA AWARD 2008
The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines.

09.11.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS JOURNAL EDITORIAL DOCUMENTS DRAMATIC INCREASE IN SURVIVAL SINCE THE 1980'S
Writing in the October 10th edition of the Journal of Clinical Oncology, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent.

06.23.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE
New Indication Provides Treatment-Free Interval As an Option

05.31.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW STUDIES SHOW LONGER SURVIVAL FOR MYELOMA PATIENTS AND IMPROVED RESPONSE TO TREATMENTS
Encouraging new findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, showing significant improvements in treating myeloma.

05.14.08  NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION FINALIZES GUIDELINES TO HELP NURSES MANAGE AND PATIENTS COPE WITH THE SIDE EFFECTS OF THERAPY
Consensus Statements Will Be Published in the Clinical Journal of Oncology Nursing and Will Be Presented in Conjunction with the Oncology Nursing Society Annual Meeting May 16th

04.21.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS THALIDOMIDE APPROVAL IN EUROPE COULD PROVIDE SURVIVAL BENEFITS TO NEWLY DIAGNOSED MYELOMA PATIENTS
The European Commission Grants Marketing Authority for Melphalan-Prednisone-Thalidomide Regimen

04.11.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® MEETS IMPORTANT QUALITY OF LIFE MEASURES

02.06.08  IMF PRESENTS THE KYLE LIFETIME ACHIEVEMENT AWARD TO MARIO BOCCADORO, MD, OF THE UNIVERSITY OF TORINO, ITALY
Founded the Italian Myeloma Study Group, a Pioneering Investigator Consortium in Europe

02.04.08  THE IMF SAYS NEWLY DIAGNOSED PATIENTS COULD BENEFIT FROM FDA "PRIORITY REVIEW" OF VELCADE® FOR FRONT-LINE USE
Priority review puts VELCADE on track for potential approval in mid-2008

01.30.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW TREATMENT REGIMEN FOR OLDER PATIENTS COULD SOON BE APPROVED IN EUROPE
Positive Opinion from EU Advisory Committee Could Mark the Return of Thalidomide to Europe

01.04.08  THE INTERNATIONAL MYELOMA FOUNDATION SAYS STUDY SHOWS 90% OVERALL RESPONSE FOR PATIENTS WITH NEW REVLIMID® COMBINATION
BiRD Study (Biaxin®-Revlimid-Dexamethasone) Provides Evidence of Deep Complete Response Rates In Newly Diagnosed Multiple Myeloma

12.11.07  THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
BANK ON A CURE® DNA Data Base also finds Genetic Link to Bone Disease and Indications for Treatment

12.10.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Survival and Longer Term Disease Control Take Precedence over Short Term Response to Treatment

12.07.07  Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers
Findings to be presented at ASH show that even without a cure there are dramatic improvements in treatment and survival for patients with myeloma.

11.21.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® EXTENDS SURVIVAL WITH POSITIVE IMPLICATIONS FOR A WIDE RANGE OF BLOOD CANCERS
Two Studies in the Prestigious New England Journal of Medicine Validate the Findings.

10.09.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW THALIDOMIDE DATA CONFIRMS SURVIVAL BENEFITS FOR OLDER PATIENTS
Findings Could Support Marketing Authorization for thalidomide in Europe

09.20.07  THE INTERNATIONAL MYELOMA FOUNDATION REPORTS THAT INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
The combination therapy of VELCADE, melphalan and prednisone (VMP) demonstrates a significant advantage for patients newly diagnosed with myeloma. The therapy is already approved for use in patients who have received a previous treatment.

08.23.07  The International Myeloma Foundation Issues Prevention and Treatment Guidelines for Firefighters for High-Risk Cancer
For firefighters safety doesn’t end when the fire is over. Studies have shown firefighters are at higher risk for myeloma, and the risk increases with length of service. Most recently, studies linked an increased risk of myeloma to exposures at the World Trade Center site following 9/11.

07.04.07  THE NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION PRESENTS “GUIDELINES FOR ENHANCED PATIENT CARE” AT INTERNATIONAL MEDICAL MEETING
NLB Poster at the International Myeloma Workshop Represents a Major Advance in Nursing Care. (Article includes PDF of poster.)

06.29.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS DATA REPORTED AT A GLOBAL MEDICAL MEETING IN GREECE DEMONSTRATES IMPROVED SURVIVAL FOR A WIDE RANGE OF MYELOMA PATIENTS
"Today we have multiple options for treatment, and for many patients survival is being measured in years, not months, with an excellent quality of life," says Susie Novis.

06.19.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS EMEA MARKETING APPROVAL OF REVLIMID® IS AN IMPORTANT ADVANCE FOR PATIENTS IN EUROPE
With today's action REVLIMID is now approved in Europe for myeloma patients who have received at least one prior therapy.

06.04.07  STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
Data Presented at the ASCO Cancer Conference

06.01.07  New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
In an article entitled "The Legacy of the World Trade Center Dust," physicians say more than 5 years after the World Trade Center disaster, "uncertainty and controversy remain about the health risks posed by inhaling dust, the subsequent fires and the cleanup effort."

05.21.07  THE INTERNATIONAL MYELOMA FOUNDATION REPORTS NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Combination Provides 43% Improvement in Time to Disease Progression

05.15.07  IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID® with Low Dose Steroids in Myeloma

04.16.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS CELGENE LAUNCHES NEW "PATIENT SUPPORT COORDINATOR" PROGRAM AT MEETING OF SUPPORT GROUP LEADERS IN PHOENIX
New Program Developed Following Meetings to Address Patient Questions and Concerns

04.04.07  THE INTERNATIONAL MYELOMA FOUNDATION SAYS CLINICAL TRIAL RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma

03.27.07  IMF Says Revlimid Approval Could Benefit Patients Throughout Europe
Patients, Advocates and Experts Applaud Positive Opinion from EU Advisory Committee

03.21.07  THE INTERNATIONAL MYELOMA FOUNDATION APPOINTS HEATHER COOPER ORTNER VICE PRESIDENT OF DEVELOPMENT
The International Myeloma Foundation (IMF) today announced the appointment of Heather Cooper Ortner as vice president of development. Heather comes to the IMF from the Brandeis-Bardin Institute where she was director of development for the past three years. Her appointment is effective immediately.

02.06.07  INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS
The survey also found that the IMF excels in areas that matter most to patients: being extremely knowledgeable about issues related to myeloma, having up-to-date information, and putting the needs of patients and caregivers as the first priority.

02.05.07  LEADING CANCER EXPERTS TO CONDUCT LOS ANGELES SEMINAR ON MYELOMA TREATMENT AS THE "NEW MODEL" FOR CANCER CARE
"Blood cancers, including myeloma, are the third most common form of cancer, and today new therapies are transforming the way we treat them," said Susie Novis, president and co-founder of the International Myeloma Foundation. "While the benefits from most cancer treatment are measured in months, we are seeing many of our patients experience long-term responses measured in years with new I.V. and oral medications."

01.11.07  The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. this Summer
Michael Tuohy, a 7-year Cancer Survivor, Diagnosed When He Was Just 36, Will Travel with His Wife and Children. Communities Who Would Like a Visit May Contact the IMF.

12.11.06  BANK ON A CURE® "GENE BANK" RESEARCHERS IDENTIFY PATHWAYS THAT MEDIATE SIDE EFFECTS FROM WIDELY-USED MYELOMA TREATMENT
Findings Explain Why Certain Patients Suffer Blood Clots from Thalidomide; and Why Aspirin Works as an Intervention

12.08.06  THE INTERNATIONAL MYELOMA FOUNDATION: MULTIPLE STUDIES AT GLOBAL CANCER CONFERENCE SHOW NEW THERAPIES CHANGING THE OUTLOOK FOR PATIENTS WITH BLOOD CANCERS
Collectively, these studies represent a significant increase in knowledge of how myeloma responds to treatment, which is already becoming applicable to other cancers.

11.28.06  The International Myeloma Foundation Establishes First-of-a-Kind Partnership With Nurses to Enhance Patient Care
Nursing Leadership Board Will Provide Education, Updates and Reviews of Medical Protocols and Trends in Supportive Care.

07.31.06  Leading Cancer Experts Conduct Philadelphia Seminar on MM Treatment as New 'Model' for Cancer Care
The International Myeloma Foundation -- a not-for-profit organization supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- is bringing leading experts to the Doubletree Hotel, August 4th and 5th, to discuss the latest trends and developments changing the face of cancer care. These new developments include the recent approval of the once controversial drug thalidomide for multiple myeloma, the anticipated approval this month of a related drug called Revlimid, and new survival data, just released at a scientific conference.

12.12.05  IMF DNA BANK IDENTIFIES GENETIC VARIATIONS RELATED TO PREDISPOSITION TO MM AND RESPONSE TO TX
The findings,presented at the 47th Annual Meeting of the American Society of Hematology (ASH), identify individual genetic differences that may be associated with risk factors for developing myeloma and with adverse reactions to therapies in patients who have myeloma.

04.05.05  New, Improved Staging System for Multiple Myeloma
Developed for Use Around the World
A new study published today on-line on the Journal of Clinical Oncology’s web site demonstrates the effectiveness of a new staging system for multiple myeloma, a cancer of the plasma cells in the bone marrow.  The new International Staging System (ISS) provides a simple prognostic factor alternative to the Durie and Salmon clinical staging system used for more than 25 years.  The collaborative efforts of the IMF International Myeloma Working Group led to the development the ISS after more than four years

04.04.05  IMF to Bring Highlights from Prestigious International Myeloma Workshop to Myeloma Patients
The IMF will be reporting highlights of the prestigious 10th International Myeloma Workshop, the premiere meeting regarding multiple myeloma. The Workshop is being held April 10-14 in Sydney, Australia. 

03.08.05  IMF Receives Four-Star Rating from America's Largest Charity Evaluator
The IMF is proud to have received a four-star rating of “Exceptional”  from Charity Navigator. The four-star rating, the highest rating available from the organization, indicates that the IMF “exceeds industry standards and outperforms most charities in its Cause.”

03.06.05  GREAT NEWS: Revlimid® Phase III Myeloma Trials to Be Unblinded Early!
Celgene Corporation reported that Revlimid, also known as lenalidomide, has shown outstanding results in the treatment of relapsed or refractory myeloma in two Phase III clinical trials.

02.01.05  IMF Applauds Medicare Decision to Expand PET Scan Coverage for Myeloma
“The IMF is extremely pleased that Medicare has expanded coverage for PET scans for myeloma patients in certain circumstances,” said Brian Durie, M.D., IMF Chairman. “We have worked hard for reimbursement because we believe PET scanning is an important tool for diagnostic evaluation, staging, and monitoring for myeloma. This is a very encouraging decision by Medicare, and an important step forward for myeloma patients.”

01.27.05  Kenneth C. Anderson, MD to Receive the IMF's Robert A. Kyle Lifetime Achievement Award
Dr. Anderson is being honored for pioneering critical advances against multiple myeloma, leading not only to improved treatments, but also to a deeper understanding of how myeloma occurs at the basic level of cells and genes.

09.09.04  IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
CDC Recognizes Excellence of Current IMF Programs, Funds Expansion of Existing Programs

08.04.04  IMF Raises Awareness of Little Known Cancer During 3rd Annual Myeloma Awareness Week (August 20 -30)
The IMF believes that raising awareness in the medical professions about multiple myeloma is a critical step toward early diagnosis and encouraging the development of new treatments.

06.04.04  International Myeloma Foundation Heralds ECOG Announcement
Phase III (E1 A00) Study Results Presented at ASCO

03.24.04  International Myeloma Foundation Supports Senator Hutchison Initiative
Program Recognizes Geraldine Ferraro’s Contributions

02.18.04  Foremost Myeloma Organization to Honor Dr. Bart Barlogie
Cancer Research Pioneer is Lifetime Achievement Award Recipient